Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22510132 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL3243144 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL2392859 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL84692 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL5494796 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL19493139 | 0.75 | MKNK1 (0.53) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| Hydrochloric Acid SCHEMBL16324142 | 0.73 | MKNK1 (0.51) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL16085053 | 0.72 | MKNK1 (0.46) | MKNK1DYRK1AKLK7DGAT1SSTR4 | |
| SCHEMBL24542638 | 0.71 | DYRK1A (0.58) | MKNK1DYRK1AKLK7PRMT5WDR77 | |
| SCHEMBL836424 | 0.71 | CYP2A6 (0.46) | MKNK1DYRK1AKDRCDK2DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133069-B1 | BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | SHENZHEN YONGZE PHARMACEUTICAL CO LTD (CN) | 2019-09-18 | — | — | EP | claimed |
| US-9969753-B2 | BCR-ABL diploid inhibitor, synthesizing method therefor, and uses thereof | SHENZHEN YONGZE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-15 | — | — | US | claimed |
| EP-3133069-A1 | BCR-ABL DIPLOID INHIBITOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Chengdu University (CN) | 2017-02-22 | — | — | EP | claimed |
| US-20170037061-A1 | BCR-ABL Diploid Inhibitor, Synthesizing Method Therefor, and Uses Thereof | SHENZHEN YONGZE PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1362050-B1 | PYRIMIDINE DERIVATIVES FOR INHIBITION OF CELL-PROLIFERATION | ASTRAZENECA AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-6844341-B2 | Pyrimidine derivatives for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2005-01-18 | — | — | US | disclosed |
| US-20040097506-A1 | Pyrimidine derivatives for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1362050-A1 | PYRIMIDINE DERIVATIVES FOR INHIBITION OF CELL-PROLIFERATION | AstraZeneca AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066481-A1 | PYRIMIDINE DERIVATIVES FOR INHIBITION OF CELL-PROLIFERATION | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097506-A1 | Pyrimidine derivatives for inhibition of cell proliferation | TYMP, TK1, TYMS | MKNK1 3504/4885DYRK1A 1800/4885KLK7 3619/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | MKNK1 4046/4885DYRK1A 4673/4885KLK7 2863/4885 |
| US-20170037061-A1 | BCR-ABL Diploid Inhibitor, Synthesizing Method Therefor, and Uses Thereof | BCR, ABL1, BOD1L1 | MKNK1 2851/4885DYRK1A 79/4885KLK7 1905/4885 |
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX6, P2RX2 | MKNK1 4424/4885DYRK1A 2248/4885KLK7 4511/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | MKNK1 3318/4885DYRK1A 4550/4885KLK7 4656/4885 |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK1, JAK3 | MKNK1 535/4885DYRK1A 508/4885KLK7 4128/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | MKNK1 1582/4885DYRK1A 3699/4885KLK7 1960/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | MKNK1 4046/4885DYRK1A 4673/4885KLK7 2863/4885 |
| US-20250368655-A1 | SMALL MOLECULE INHIBITORS OF BCR-ABL | ABL1, BCR, LTK | MKNK1 315/4885DYRK1A 257/4885KLK7 3656/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | MKNK1 66/4885DYRK1A 1099/4885KLK7 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.